Anti-growth factor therapy for lung cancer

Drug Resistance Updates

Volumn 1, Issue 6, 1998, Pages 377-388

  Chan, Daniel C ^a,b   Geraci, Mark ^a   Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Carcinex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000853486     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80013-7     Document Type: Review

References (112)

1. Cook R.M., Miller Y.E., and Bunn Jr. P.A. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 17 (1993) 69-141
2. Cuttitta F., Carney D.N., Mulshine J., et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316 (1985) 823-826
3. Cohen A.J., Bunn Jr. P.A., Franklin W., et al. Variable expression in human lung inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 56 (1996) 831-839
4. Shipp M.A., Tarr G.E., Chen C., et al. CD 10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 88 (1991) 10662-10666
5. Dhanasekaran N., Heasley L.E., and Johnson G.L. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev 16 (1995) 259-270
6. 16. J Biol Chem 271 (1996) 349-354
7. Mitchell F.M., Heasley L.E., Qian N.X., et al. Differential modulation of bombesin-stimulated phospholipase Cβ and mitogen-activited protein kinase activity by [D-Arg1, D-Phe5, D-Trp7,9, Leu11) substance P. J Biol Chem 270 (1995) 8623-8628
8. Jarpe M.B., Knall C., Mitchell F.M., et al. (D-Arg1, D-Phe5, D-Trp7,9,Leu11) Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273 (1998) 3097-3104
9. Woll P.J., and Rozengurt E.A. (D-Arg1, D-Phe5, D-Trp7,9, Leu11) substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci USA 85 (1988) 1859-1863
10. Bunn Jr. P.A., Chan D., Dienhart D.G., et al. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res 52 (1992) 24-31
11. Bunn Jr. P.A., Chan D., Stewart J., et al. Effects of neuropeptide analogs on calcium flux and proliferation in lung cancer cell lines. Cancer Res 54 (1994) 3602-3610
12. Nakanishi Y., Mulshine J.L., Kasprzyk P.G., et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 82 (1988) 354-359
13. Vostrys M., Moran P., and Seligman P. Transferrin synthesis by small-cell lung cancer cells acts as an autocrine regulator of cellular proliferation. J Clin Invest 82 (1988) 331-339
14. Reeve J.G., Payne J.A., and Bleehen N.M. Production of immunoreactive insulin-like growth factor-I (IGF-1) and IGF-1 binding proteins by human lung tumours. Br J Cancer 61 5 (1990) 727-731
15. Carpenter G., and Cohen S. Epidermal growth factor. Ann Rev Biochem 48 (1983) 193-216
16. Downward J., Yarden Y., Mayes E., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307 (1984) 521-527
17. Yamamoto T., Kamata M., Kawano H., et al. High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res 46 (1986) 414-416
18. Kelley M.J., Linnoila R.I., Avis I.L., et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing patients with small cell lung cancer. Chest 112 (1997) 256-261
19. Fan Z., Masui H., Atlas F., and Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53 (1993) 4322-4328
20. Bos M., Mendelsohn J., Bowden D., et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc Am Soc Clin Oncol 15 (1996) 443
21. Divigi C.R., Welt S., Dris M., et al. Phase I and imaging trial of indium III-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Instit 83 (1991) 97-104
22. Falcey J., Pfister D., Cohen R., et al. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients with head and neck or lung carcinomas. Proc Am Soc Clin Oncol 16 (1997) 383a
23. Fan Z., Baselga J., Masui H., and Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53 (1993) 4637-4642
24. Layton J.E., Scanlon D.B., Soveny C., and Morstyn G. Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro. Cancer Res 48 (1988) 4783-4789
25. Trepel J.B., Moyer J.D., Cuttitta F., et al. A nobel bombesin receptor antagonist inhibits autocrine signals in a small-cell lung carcinoma cell line. Biochem Biophy Res Comm 156 (1988) 1383-1389
26. Bunn Jr. P.A., Dienhart D.G., Chan D., et al. Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways. Proc Natl Acad Sci USA 87 (1990) 2162-2166
27. North W.G., Fay M.J., Lango K.A., and Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifacited role for this neuropeptide. Cancer Res 58 (1998) 1866-1871
28. 2+ mobilization and clonal growth. Cancer Res 53 (1993) 5208-5213
29. Sethi T., and Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res 51 (1991) 3621-3623
30. Langdon S.P., Sethi T., Ritchie A., et al. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vitro. Cancer Res 52 (1992) 4554-4557
31. 839 GRP. Cancer Res 57 (1997) 290-294
32. 389 EGF, epidermal growth factor (EGF) receptor - targeted fusion toxins. J Biol Chem 51 (1991) 21118-21124
33. Pai L.H., Gallo M.G., FitzGerald D.J., and Pastan I. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). Cancer Res 51 (1991) 2808-2812
34. Yamazaki H., Kijima H., Ohnishi Y., et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Nat Cancer Inst 90 (1998) 581-587
35. Lee C.T., Wu S., Gabrilovich D., et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56 (1996) 3038-3041
36. Bunn Jr. P.A., Chan D., Helfrich B., et al. Recombinant neutral endopeptidase inhibits the in vitro and in vivo growth of human lung cancers with neuroendocrine features. Lung Cancer 18 (1997) 147-149
37. Bos M., Mendelsohn J., Kim Y., et al. PD 153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3 (1997) 2099-2106
38. Fathi Z., Way J.W., Corjay M.H., et al. Bombesin receptor structure and expression in human lung carcinoma cell lines. J Cell Bioch (Suppl) 24 (1996) 237-246
39. Birch R.M., and Kyle D.G. Mini-review: recent developments in the understanding of bradykinin receptors. Life Sci 50 (1992) 829-838
40. Chan D., Gera L., Helfrich B., et al. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immunopharm 33 (1996) 201-204
41. Beckman A., Helfrich B., Bunn Jr. P.A., and Heasley L.E. Expression of catalytically inactive phospholipase c beta disrupts phospholipase c beta and nitrogen-activated protein kinases signalling and inhibits small-cell lung cancer growth. Cancer Res 58 (1998) 910-913
42. Taylor S.J., Chae H.Z., Rhee S.G., and Exton J.H. Activation of the beta I isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 350 (1991) 516-518
43. Prasad M.V., Dermott J.M., Heasley L.E., et al. Activation of Jun kinase/stress-activated protein kinase of GTP-ase deficient mutants of G-alpha 12 and G alpha 13. J Biol Chem 270 (1995) 18655-18659
44. Buhl A.M., Johnson N.L., Dhanasekaran N., and Johnson G.L. G alpha 12 and G alpha 13 stimulate Rho dependent stress fiber formation and focal adhesion assembly. J Biol Chem 270 (1995) 24631-24634
45. Kozasa T., Jiang X., Hart M.J., et al. p115 Rho GEF, a GTPase activating protein for G alpha 12 and G alpha 13. Science 280 (1998) 2109-2111
46. Hart M.J., Jiang X., and Kozasa T. Direct stimulation of the guanine nucleotide exchange activity of p115 Rho GEF by G alpha 13. Science 280 (1998) 2112-2114
47. Viallet J., Sharoni Y., Frucht H., et al. Cholera toxin inhibits signal tranduction by several mitogens and the in vitro growth of human small cell lung cancer. J Clin Invest 86 (1990) 1904-1912
48. Butterfield L., Storey B., Maas L., and Heasley L.E. C-Jun NH2 -terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem 272 (1997) 10110-10116
49. Reeve J.G., and Bleehen N.M. (D-Argl, D-Phe5, D-Trp7,9, Leu11) substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophy Res Comm 199 3 (1994) 1313-1319
50. Seckl M.J., Higgins T., Widmer F., and Rozengurt E. (D-Arg1, D-Phe5, D-Trp7,9, Leu 11) substance P a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small-cell lung cancer cells. Cancer Res 57 (1997) 51-54
51. Chan D., Gera L., Helfrich B., et al. A new class of peptide antagonist dimers inhibits the growth of human lung cancer cells in vitro and in vivo. Proc Am Assoc. Cancer Res 38 (1997) 232
52. Chan D., Gera L., Helfrich B., et al. Novel cytotoxic bradykinin antagonist dimers inhibit human lung cancer growth in vitro and in vivo. Lung Cancer 18 Suppl. 1 (1997) 150
53. Chan D., Helfrich B., Gera L., et al. Combination of peptide antagonist monomers and dimers enhances killing of human lung cancer cells. Lung Cancer 18 Suppl 1 (1997) 149
54. Chan D., Whalley E., Helfrich B., et al. Effect or linker length and type on the cytotoxic activity of Bradykinin antagonist dimers in human lung cancer cells in vitro. Proc Am Assoc Cancer Res 37 (1996) 417
55. Chan D., Gera L., Helfrich B., et al. Novel cytolytic Bradykinin antagonist dimers inhibit human lung cancer growth. Proc Am Assoc Cancer Res 37 (1996) 417
56. Vavrek R.J., and Stewart J.M. Competitive antagonists of bradykinin. Peptides 6 2 (1985) 161-164
57. Cheronis J.C., Whalley E.T., and Nguyen K.T. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem 35 (1992) 1563-1572
58. Gera J., Stewart J.M., Whalley E.T., et al. A new class of potent bradykinin antagonist dimers. Immunopharmacology 33 (1996) 178-182
59. Whalley E.T., Hanson H.T., Stewart J.M., and Gera L. Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. Can J Physio Pharmacol 75 6 (1997) 629-632
60. Hock F.J., Wirth K., Albus U., et al. HOE-140 a new potent and long acting bradykinin antagonists. Br J Pharmacol 102 (1991) 769-773
61. Fisher E.R., and Faulson J.D. A new in vitro cell line established from human large cell variant of oat cell lung cancer. Cancer Res 38 (1978) 3830-3835
62. Koros A.M., Klein E.C., Pan S., et al. Stability and utility fo the unique human small cell carcinoma SHP-77. Cancer Res 45 (1985) 2725-2731
63. Chan D., Chuang N., Jewett P., et al. Reversal of multidrug resistance by a dexniguldipine (B8509-035), niguldipine and verapamil in small cell lung carcinoma cell lines. Proc Am Assoc Cancer Res 34 (1993) 323
64. Chan D., Helfrich B., Chuang N., et al. Syngerism of MDR modulators with adriamycin in non-selected multi-drug resistant lung cancer cells. Proc Am Assoc Cancer Res 38 (1997) 591
65. Campling B.G., Young L.C., Baer K.A., et al. Expression of the MRP and MDRI multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3 (1997) 115-122
66. Roninson I. The role of MDR1 (Poglycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43 (1992) 95-102
67. Keizer H., Schuurhuis G., Broxterman H.J., et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49 (1989) 2988-2993
68. Kuiper C.M., Broxterman H.J., Baas F., et al. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1 (1990) 35-41
69. Chou T.C., and Talalay P.T. Quantitative analysis of dose-effects relationships: The combined effects of multiple drugs or enzyme inhibitions. Adv Enzyme Regul 22 (1984) 27-55
70. Oates J.A., Fitzgerald G.A., Branch R.A., et al. Medical progress: clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 319 (1988) 689-698
71. Smith W.L. The eicosanoids and their biochemical mechanism of action. Biochemistry 259 (1989) 315-324
72. Plescia O.J., Smith A.H., and Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 72 (1975) 1848-1854
73. Hwang D. Essential fatty acids and immune response. FASEB J 3 (1989) 2052-2061
74. Taffet S.M., Pace J.L., and Russell S.W. Lymphokine maintains macrophage activation for tumor cell killing by interfering with the negative regulatory effect of prostaglandin E2. J Immunol 127 (1981) 121-124
75. Beckerman K.P., Schreiber R.D., and Needleman P. Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo. Prosta Leuk Ess Fat Acids 47 (1992) 231-238
76. Polverini P.J. Macrophage-induced angiogenesis: a review. In: Song C. (Ed). Macrophage-derived cell regulatory factors (1989), Karger, Cytokines Basel 54-73
77. Nakaguchi K., Nishijima J., Lgawa M., et al. Purification and some properties of membrane-associated phospholipase A2 of human spleen. Enzyme 35 (1987) 2-12
78. Takayama K., Kudo I., Kim D.K., et al. Purification and characterization of human platelet phospholipase A2 which preferentially hydrolyzed an arachidonyl residue. FEBS Lett 282 (1991) 326-330
79. Heinrikson R.L., Krueger E.T., and Leim P.S. Amino acid sequence of phospholipase A2-Alpha from the venom of Crotalus Adamanteus. A new classification of phospholipase A2 based upon structural determinants. J Biol Chem 252 (1977) 4913-4921
80. Ono T., Tojo H., Kuramitsu S., et al. Purification and characterization of a membrane-associated phospholipase A2 from rat spleen. Its comparison with cytosolic phospholipase A2 S-1. J Biol Chem 263 (1988) 5732-5738
81. (2+) dependent translocation domain with homology to PKC and GAP. Cell 65 (1991) 1043-1051
82. Seilhamer J.J., Pruzanski W., Vadas P., et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem 264 (1989) 5335-5338
83. Yhamashita S.I., Ogawa M., Sakamoto K., et al. Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228 (1994) 91-99
84. Abe T., Sakamoto K., Kamohara H., et al. Group II phospholipase A2 in increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer 74 (1997) 245-250
85. Wolbink G.J., Schalkwijk C., Baars J.W., et al. Therapy with interleukin-2 induces the systemic release of phospholipase A2. Can Immunol Immunother 41 (1995) 287-292
86. Heasley L.E., Thaler S., Nicks M., et al. Induction of cytosolic phosphilipase A2 by oncogenic ras in human non-small cell lung cancer. J Biol Chem 272 (1997) 14501-14504
87. Honn K.V., Tang D.G., Xiang G., et al. I2-lipoxygenases and I2(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev 13 (1994) 365-396
88. in press. Moody T.W., Leyton J., Martinez A., et al. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res (1998)
89. Tang D.G., Grossi I.M., Tang K.Q., et al. Inhibition of TPA and as(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects. Int J Cancer 60 (1995) 418-425
90. Tang D.G., Chen Y.Q., and Honn K.V. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 93 (1996) 5241-5246
91. Sirois J., Levy L.O., Simmons D.L., and Richards J.S. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells: Identification of functional and protein binding regions. J Biol Chem 268 (1993) 12199-12206
92. Kujubu D.A., and Herschman H.R. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 267 (1992) 7991-7994
93. Smith W.L., Marnett L.J., and DeWitt D.L. Prostaglandin and thromboxane biosynthesis. Pharmac Ther 49 (1991) 153-179
94. Frangos J.A., Eskin S.G., McIntire L.V., and Ives C.L. Flow effects on prostacyclin production by cultured human endothelial cells. Science 227 (1985) 1477-1479
95. Kujubu D.A., Fletcher B.S., Varnum B.C., et al. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266 (1991) 12866-12872
96. Xie W., and Herschman H.R. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270 (1994) 27622-27628
97. Kurchera W., Jones D.A., Matsunami N., et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93 (1996) 4816-4820
98. Kargman S.L., O'Neil G.P., Vickers P.J., et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55 (1995) 2556-2559
99. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med 328 (1993) 1313-1316
100. Thun M., Namboodiri M., and Heath C. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 (1991) 1593-1596
101. Thun M., Namboodiri M., Calle E.E., et al. Aspirin use and risk of fatal cancer. Cancer Res 53 (1993) 1322-1327
102. Peleg I.I., Maibach H.T., Brown S.H., and Wilcox C.M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154 (1994) 394-399
103. Piazza G.A., Alberts D.S., Hixson L.J., et al. Sulindac sulfone inhibits azoxymethase-induced colon carcinogenesis in rats with reducing prostaglandin levels. Cancer Res 57 (1997) 2909-2915
104. Piazza G.A., Rahm A.K., Finn T.S., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57 (1997) 2452-2459
105. Hohn K.V., Cicone B., and Skoff A. Prostacyclin: A potent antimetastatic agent. Science 212 (1981) 1270-1272
106. Schneider M.R., Tang D.G., Schirner M., et al. Prostacyclin and its analogues: Antimetastic effects and mechanisms of action. Cancer Metastasis Rev 13 (1994) 349-364
107. Schirner M., and Schneider M.R. Inhibition of metastasis by Cicaprost in rats with established SMTA2 mammary carcinoma growth. Cancer Detec and Preven 21 (1997) 44-50
108. Barst R.J., Rubin L.J., McGoon M.D., et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
109. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
110. Geraci M.W., Gao B., Shepherd D., et al. Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice. Chest 114 (1998) 99S
111. Keith R.L., Miller Y.E., Malkinson A.M., et al. Selective pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of adenocarcinoma: Implications for chemoprevention and gene therapy. Sixth SPORE Investigator's Workshop. Rockville, MD, July 12-14 (1998)
112. Heasley L.E., and Johnson G.L. Signal Transduction Abnormalities in Lung Cancer. In: Kane M.A., and Bunn Jr. P.A. (Eds). Lung Biology in Health and Disease: Biology of Lung Cancer (1998), Marcel Dekker, New York 371-390